Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProLectin-V
- Development stage
- Preclinical
- Lead developer
- BioXyTran
- Administration
- Intravenous
01
Overview
ProLectin-V is an investigational, intravenously administered carbohydrate-based galectin antagonist being developed by BioXyTran. It is designed to target Galectin-3, a carbohydrate-binding lectin involved in viral entry, immune regulation, and inflammatory signaling. By inhibiting Galectin-3 and potentially interacting with galectin-like folds on viral surfaces, ProLectin-V aims to block viral attachment and entry into host cells. The drug is currently in preclinical development for the treatment of viral infections and inflammatory conditions, including monkeypox, Ebola virus disease, and conjunctivitis.
02
Targets
LGALS3 (Galectin-3)
Beyond the preview
Go deeper on ProLectin-V.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProLectin-V.